With 2026 less than 5 months away, the employer healthcare landscape is facing one of its most significant cost escalations in more than a decade. While employers have weathered cycles of benefit inflation before, the combination of rising medical inflation, unprecedented specialty drug costs, and post-pandemic utilization surges is creating a “perfect storm” for plan sponsors. What’s different this time is the scope and speed of the increase—forcing proactive planning well ahead of open enrollment season.

Healthcare Cost Trends Driving the 2026 Surge

According to Mercer’s 2025 Survey on Health and Benefit Strategies, 51% of large employers (those with 500 or more employees) expect to shift more costs to employees in 2026. This represents a significant jump from 45% last year and underscores the financial strain many organizations are experiencing. Employers saw 2025 at a near 6% increase in benefit costs compared to 2024, with projections for 2026 expected to be even higher once pharmacy and claims data are finalized later this year.

One key driver is higher-than-anticipated utilization of elective procedures and preventive care services that were delayed during the pandemic. Hospitals and physician groups are also adjusting reimbursement rates upward to counter inflation, labor shortages, and supply chain challenges—costs that ultimately flow through to employer-sponsored health plans.

The GLP-1 Effect: When One Drug Class Moves the Needle

Of all cost drivers, few are generating as much boardroom discussion as GLP-1 medications such as Ozempic®, Wegovy®, and Zepbound®. These drugs, originally approved for Type 2 diabetes, have now become widely prescribed for weight management—creating massive cost implications for employer pharmacy benefits. Mercer reports that 77% of employers list GLP-1 cost management as a top pharmacy priority for 2026. This is not simply about formulary placement; it’s about whether long-term coverage is sustainable at current price points.

The scale of the issue is striking. In some health plans, GLP-1s already account for more than 10% of total annual prescription drug spend. With annual per-patient costs often exceeding $10,000, even modest increases in utilization can have a disproportionate impact on total plan spend. This trend has led many employers to reevaluate coverage terms, prior authorization requirements, and step-therapy protocols.

Beyond Drugs: Additional Cost Pressure Points

While GLP-1s dominate headlines, they are far from the only concern. Inpatient hospital costs are rising, driven by higher acuity cases and staffing shortages in nursing and specialized care units. Outpatient surgery centers—once the darlings of cost containment—are now reporting 3–5% annual price increases, eroding some of their competitive advantage. Mental health service utilization remains elevated compared to pre-pandemic baselines, and many employers are expanding coverage in this area for recruitment and retention purposes, further increasing total benefit spend.

Employers are also contending with tighter carrier underwriting standards, especially in stop-loss insurance markets. For self-funded plans, this means higher attachment points and premiums, particularly for groups with poor claims experience or high-cost claimants on specialty drugs.

Strategic Employer Responses: 2025–2026 Playbook

• Plan Design Adjustments: Employers are preparing to implement higher deductibles, increased copays, and revised out-of-pocket maximums. While these tactics are not new, the degree of change may be more aggressive than in past cycles.
• Alternative Plan Models: Around 35% of employers are exploring non-traditional models for 2026, such as variable copay structures, reference-based pricing, and direct primary care arrangements. These models aim to drive cost transparency and shift utilization toward higher-value providers.
• Pharmacy Benefit Overhauls: Strategies include moving GLP-1s to higher formulary tiers, requiring enrollment in wellness programs for coverage eligibility, and negotiating value-based PBM contracts where payment is tied to clinical outcomes.
• Care Navigation Programs: Employers are investing in digital navigation tools that guide employees toward lower-cost, high-quality care settings. Early results suggest these tools can reduce unnecessary ER visits and imaging costs.
• Telehealth Optimization: Rather than simply offering telehealth as a parallel service, some employers are integrating it into primary care models to reduce specialist referrals and avoid unnecessary in-person visits.

Balancing Cost Control with Retention and Equity

Any decision to increase employee cost sharing must be weighed against retention risk. In a competitive labor market, overly aggressive plan design changes can erode employee trust and lead to turnover—particularly in hard-to-fill roles. Tribal and mission-driven organizations face the added consideration of aligning benefits with cultural values and community priorities.

Employers are increasingly modeling plan changes to assess their impact on different employee segments before finalizing decisions.

Five Actions Employers Should Take Before Year-End

• Conduct Detailed Cost Modeling: Use current claims data to model 2026 scenarios, including varying levels of GLP-1 utilization and specialty drug pipeline projections.
• Explore Hybrid Benefit Designs: Consider options such as high-performance networks or tiered copay structures that maintain choice while incentivizing cost-effective care.
• Renegotiate Vendor Contracts: Review PBM, carrier, and stop-loss agreements for opportunities to add transparency clauses, performance guarantees, and alternative pricing models.
• Invest in Employee Education: Begin communicating the “why” behind plan changes early. Employees who understand the cost pressures driving decisions are more likely to accept changes constructively.
• Integrate Wellbeing and Cost Strategies: Pair benefit cost management with programs that improve long-term employee health, such as chronic condition management, mental health support, and preventive care incentives.

Atria’s Advisory Role in a Volatile Market

At Atria, we help employers navigate the complexities of benefit planning in a high-cost environment. Our approach blends data analytics, market benchmarking, and organizational values alignment to deliver benefit strategies that are both financially sustainable and culturally resonant. This includes:

• In-depth claims analysis and forecasting tailored to your industry and workforce
• Design and implementation of alternative plan models that support cost transparency
• Pharmacy strategy development, including specialty drug cost containment
• Employee engagement frameworks that drive understanding and satisfaction

The 2026 healthcare cost surge is coming. Whether it becomes a budget crisis or a managed transition will depend on the steps you take now. Contact Atria to build a proactive, data-driven benefits strategy that safeguards both your financial stability and your employees’ wellbeing.

This article is for informational purposes only and should not be considered legal or tax advice.